- Research article
- Open Access
- Open Peer Review
Lifestyle factors affecting gastroesophageal reflux disease symptoms: a cross-sectional study of healthy 19864 adults using FSSG scores
BMC Medicine volume 10, Article number: 45 (2012)
Gastroesophageal reflux disease (GERD) is a very common disorder worldwide, comprised of reflux esophagitis (RE) and non-erosive reflux disease (NERD). As more than half of GERD patients are classified into the NERD group, precise evaluation of bothersome epigastric symptoms is essential. Nevertheless, compared with many reports targeting endoscopic reflux esophagitis, large-scale studies focusing on GERD symptoms have been very scarce.
To elucidate lifestyle factors affecting GERD symptoms, 19,864 healthy adults in Japan were analyzed. Sub-analyses of 371 proton pump inhibitor (PPI) users and 539 histamine H2-receptor antagonist (H2RA) users were also performed. Using the FSSG (Frequency Scale for the Symptoms of GERD) score as a response variable, 25 lifestyle-related factors were univariately evaluated by Student's t-test or Pearson's correlation coefficient, and were further analyzed with multiple linear regression modelling.
Average FSSG scores were 4.8 ± 5.2 for total subjects, 9.0 ± 7.3 for PPI users, and 8.2 ± 6.6 for H2RA users. Among the total population, positively correlated factors and standardized coefficients (β) for FSSG scores are inadequate sleep (β = 0.158), digestive drug users (β = 0.0972 for PPI, β = 0.0903 for H2RA, and β = 0.104 for others), increased body weight in adulthood (β = 0.081), dinner just before bedtime (β = 0.061), the habit of midnight snack (β = 0.055), lower body mass index (β = 0.054), NSAID users (β = 0.051), female gender (β = 0.048), lack of breakfast (β = 0.045), lack of physical exercise (β = 0.035), younger age (β = 0.033), antihyperglycemic agents non-users (β = 0.026), the habit of quick eating (β = 0.025), alcohol drinking (β = 0.025), history of gastrectomy (β = 0.024), history of cardiovascular disease (β = 0.020), and smoking (β = 0.018). Positively correlated factors for PPI users are female gender (β = 0.198), inadequate sleep (β = 0.150), lack of breakfast (β = 0.146), antihypertensive agent non-users (β = 0.134), and dinner just before bedtime (β = 0.129), whereas those for H2RA users are inadequate sleep (β = 0.248), habit of midnight snack (β = 0.160), anticoagulants non-users (β = 0.106), and antihypertensive agents non-users (β = 0.095).
Among many lifestyle-related factors correlated with GERD symptoms, poor quality of sleep and irregular dietary habits are strong risk factors for high FSSG scores. At present, usual dose of PPI or H2RA in Japan cannot fully relieve GERD symptoms.
Gastroesophageal reflux disease (GERD) is defined as a condition of troublesome symptoms and/or complications caused from the reflux of stomach contents . Despite the high morbidity rate at present, the number of GERD patients is still increasing worldwide . Most GERD patients presented esophageal syndromes such as heartburn, chest pain, dysphagia, odynophagia, and so on, though it has recently become clear that not a few latent GERD subjects are suffering from extraesophageal syndromes . Esophageal GERD includes two pathophysiological states: reflux esophagitis (RE, diagnosed by endoscopic observation) and non-erosive reflux disease (NERD, mainly diagnosed on the basis of the upper gastrointestinal symptoms). Most studies reported that NERD patients occupy more than half of all GERD patients [3–5].
Nowadays, it has been the worldwide consensus that the goals of GERD therapy should be based on the improvement of various symptoms and prevention of complications, such as esophageal strictures, gastrointestinal bleeding and Barrett's esophagus [6–9]. Actually, most of the guidelines for GERD emphasize relieving the bothersome symptoms rather than preventing the endoscopic esophageal injury [10–12], probably reflecting the high prevalence of endoscopy-negative cases among GERD patients [4, 5]. Therefore, precise evaluation of GERD symptoms is quite important for not only grasping the patient's disorder but also assessing effectiveness of the therapy. To assess the GERD symptoms, several questionnaires have been proposed, such as QUEST , Manterola's Scale , FSSG (Frequency Scale for the Symptoms of GERD) , Zimmerman's Scale , and so forth. Whereas typical symptoms of GERD are heartburn and regurgitation , it is well known that GERD patients present very diverse symptoms . In the present study, we chose FSSG scoring, as it can evaluate not only the acid-reflux related symptoms but also the dyspeptic symptoms [15, 18].
There have been many studies which examined the relation between GERD (especially reflux esophagitis) and predictive background factors such as age [19, 20], gender [19, 20], body mass index (BMI) , obesity , hiatus hernia , and so on, but large-scale studies focusing on GERD symptoms alone have been very few. Since it is a very common disease affecting millions of people around the globe, it is quite important to clarify the causative lifestyle factors affecting various GERD symptoms. Therefore, one of our aims in this study is to analyze the correlation between GERD symptoms and background variables, especially focused on lifestyle factors.
Another aim of our study is to evaluate the efficacy of proton pump inhibitors (PPI) and histamine H2-receptor antagonists (H2RA), both of which are the most popular drugs used for GERD treatment world-wide. The FSSG scores of PPI users and H2RA users were analyzed in the same univariate and multivariate manner, which would illuminate actual background factors of GERD patients under medical treatment, and also could clarify the efficacy of medication upon habitual antacid users. Through the cross-sectional analysis of the large-scale healthy population, our study should shed light on the pathophysiology of GERD symptoms.
The study population was 20,773 subjects who received medical checkups at Kameda Medical Center Makuhari (Chiba-shi, Chiba, Japan) in 2010, and also approved their entry into our study. If the subject had a health checkup twice in 2010, the former data were used. Criteria for exclusion were age less than 20 years and insufficient answers to the questionnaire (22 questions under-mentioned and 10 questions from FSSG). To avoid interviewer bias, the questionnaire was self-administered for all the participants. This study was approved by the ethics committees of the University of Tokyo, and written informed consents were obtained from all study participants according to the Declaration of Helsinki.
FSSG (Frequency Scale for the Symptoms of GERD) and questionnaire
FSSG is a widely used questionnaire for the diagnosis of GERD [23–25], and also for evaluating the effectiveness of the treatment [15, 26]. In the previous study, comparing FSSG with QUEST, it was validated that there was no difference between both questionnaires in sensitivity, specificity and accuracy for any condition . The twelve questions of the FSSG cover various symptoms related to the upper gastrointestinal tract as well as psychosomatic symptoms  (Figure 1); a score of more than seven points suggested the presence of GERD in the respondent [15, 18].
In this study, all the participants were asked to respond to the FSSG scale questionnaire, along with another detailed questionnaire consisting of 22 original questions. Additional 22 questions include enquiries about symptoms related to the upper gastrointestinal tract, medical history, family history, lifestyle factors and so on (Figure 1).
Univariate analysis was performed with the FSSG score as a response variable and 25 background factors (age, gender, BMI, and 22 answers to the questionnaires) as explanatory variables. Student's t-test (P < 0.05) or Pearson's correlation coefficient (P < 0.05) were used for univariate analyses. A multiple linear regression model was next applied for predictive background factors selected from the univariate analyses. A two-sided P-value of less than 0.05 was considered statistically significant. All statistical analyses were performed using SAS version 8.2 (SAS Institute Inc., Cary, NC, USA).
Characteristics of study subjects
Of the 20,773 potential subjects for this study (Figure 2), we selected 19,864 subjects (11,493 men and 8,371 women) with a mean age of 50.2 ± 9.4 years (range 20 to 87 years). A total of 371 PPI users comprised of 239 men and 132 women with a mean age of 55.8 ± 9.9 years (range 27 to 87 years), whereas 539 H2RA users comprised of 332 men and 207 women with a mean age of 52.9 ± 9.8 years (range 27 to 87 years).
The distribution of FSSG scores (0 to 48) among the total subjects, PPI users, and H2RA users are shown in Figure 3. Average FSSG scores of subjects in the three groups are 4.8 ± 5.2 for total subjects, 9.0 ± 7.3 for PPI users, and 8.2 ± 6.6 for H2RA users. Both the PPI and H2RA users have obviously higher FSSG scores than total study participants (P < 0.0001).
Positively correlated factors of FSSG scores among the total 19,864 subjects
FSSG scores of the 19,864 study subjects in the presence or absence of 25 background factors (age, BMI, gender, and answers to the 22 questions) are shown in Table 1. Based on the univariate analyses, 18 factors show positive correlation with FSSG scores: younger age, female gender, history of gastrectomy, users of digestive drugs (PPIs, H2RAs, and others), NSAID users, steroid users, antihyperglycemic agent non-users, history of cardiovascular disease, increased body weight in adulthood, lack of habitual physical exercise, habit of midnight snack, inadequate sleep, frequent lack of breakfast, dinner just before bedtime, the habit of quick eating, and the habit of smoking.
We next performed the multivariate analysis, focusing on the above-mentioned univariately significant factors together with BMI and drinking. Positively correlated factors of FSSG score, in order of significance, are inadequate sleep, users of digestive drugs (PPIs, H2RAs, and others), increased body weight in adulthood, habitual dinner just before bedtime, habit of midnight snack, lower BMI, NSAID users, female gender, frequent lack of breakfast, lack of habitual physical exercise, younger age, antihyperglycemic agents non-users, habit of quick eating, habit of alcohol drinking, history of gastrectomy, history of cardiovascular disease, and habit of smoking (Table 2).
Positively correlated factors of FSSG scores among the PPI users
FSSG scores of the 371 PPI users in the presence or absence of 23 background factors were next analyzed (Additional file 1, Table S1). Based on the univariate analyses, 13 factors show positive correlation with FSSG scores: female gender, users of other digestive drugs, anticoagulants non-users, antihypertensive agents non-users, antihyperglycemic agents users, antihyperlipidemic agents non-users, history of cerebrovascular disease, lack of habitual physical exercise, habit of midnight snack, inadequate sleep, frequent lack of breakfast and dinner just before bedtime.
This result was followed by the multivariate analysis, focusing on the abovementioned significant 13 factors and four other essential factors (BMI, NSAID users, drinking and smoking). Among the PPI users, positively correlated factors of FSSG score in order of significance are female gender, inadequate sleep, frequent lack of breakfast, antihypertensive agent non-users, and dinner just before bedtime (Table 3).
Positively correlated factors of FSSG scores among the 539 H2RA users
FSSG scores of 539 H2RA users in the presence or absence of 23 background factors were further analyzed (Additional file 1, Table S2). Based on the univariate analyses, positively correlated factors of the FSSG score are younger age, female gender, anticoagulants non-users, antihypertensive agent non-users, history of cerebrovascular disease, history of cardiovascular disease, habit of midnight snack, inadequate sleep, frequent lack of breakfast and dinner just before bedtime.
This result was followed by the multivariate analysis, focusing on the abovementioned significant 10 factors and 4 other essential factors (BMI, NSAID users, alcohol drinking, and smoking). Among the H2RA users, positively correlated factors of FSSG score in order of significance are inadequate sleep, habit of midnight snack, anticoagulant non-users and antihypertensive agent non-users (Table 4).
Many lifestyle-related factors show strong correlation with GERD symptoms
Of the 19 significant factors, 8 are obvious lifestyle factors (Table 2). "Increased body weight in adulthood" and "BMI" are also strongly related to the subject's lifestyle. Therefore, except for use of digestive drugs (PPIs, H2RAs, and others), the top five correlated factors with GERD symptoms are lifestyle-related (Table 2). Alcohol consumption and habitual smoking have been reported to be putative risk factors for GERD , though it has still been controversial for their association with GERD "symptoms". Our present cross-sectional study demonstrated significant correlation of alcohol and smoking with GERD symptoms, but their influences upon FSSG scores were not so strong: the other eight lifestyle-related factors had much stronger influence on GERD symptoms (Table 2).
For BMI and obesity, our result was interesting; increased body weight in adulthood is a strong risk factor of GERD, whereas the BMI is negatively correlated with FSSG scores (Table 2). Unlike most previous studies [27–29], showing the positive correlation of obesity or overweight with erosive reflux esophagitis and Barrett's esophagitis, mere symptoms of GERD were evaluated in our study. Therefore, subjects with higher FSSG scores should comprise not only the reflux esophagitis (RE) patients, but also much higher numbers of patients suffering from NERD. The above-mentioned intriguing results for BMI and body weight gain may reflect the fact that subjects with GERD symptoms include two pathophysiologically entirely different disorders: reflux esophagitis (RE) and non-erosive reflux disease (NERD).
Poor quality of sleep and irregular dietary habits are the most significant risk factors for GERD symptoms
From our results, it is suggested that good quality of sleep, orderly eating habits and body weight control are important for avoiding GERD symptoms. In particular, inadequate sleep is a very strong background factor, not only in the total population (Table 2) but also among the antacid users (Tables 3 and 4). Nocturnal GERD is thought to be caused by such things as a decrease in esophageal peristalsis, diminished salivary production during sleep, decline of the upper esophageal sphincter basal pressure, reduced conscious-dependent behavior during sleep, distended stomach due to intragastric food, frequent lower esophageal sphincter relaxation in the supine position, and so on [30, 31]. It is well-known that nighttime GERD symptoms are the crucial cause of sleep disorders [32, 33], but recent studies also suggested that a link between sleep problems and GERD might be bidirectional, for example, due to the influence of sleep stages on esophago-upper esophageal sphincter contractile reflex  or due to reinforcing perception of intra-esophageal acid . Therefore, improving quality of sleep might be essential for relieving GERD symptoms.
Our results also indicated that dietary habits have significant correlation with FSSG scores (Table 2). Although there have been very few reports showing the effect of dietary habits upon pathogenesis of GERD , our results showed an obvious correlation between GERD symptoms and dietary habits. Accordingly, such dietary habits as the following should be avoided: 1) having dinner a few hours before going to bed, 2) the habit of eating a midnight snack, 3) frequently going without breakfast, and 4) the habit of quick eating. It should be noteworthy that these four diet-related factors present more significant effects than alcohol or smoking on GERD symptoms (Table 2).
Medication of PPIs or H2RAs is not enough to relieve the GERD symptoms
Among 19 correlated background factors, medication with digestive drugs (PPIs, H2RAs and others) shows a high correlation with FSSG scores (Table 2). Based on a meta-analysis of many trials compared with placebo , both PPIs and H2RAs have been proved to be effective in the treatment of reflux esophagitis (RE). These two antacids are the common drugs for GERD treatment, and it has been proved that PPIs are better than H2RAs in the treatment of RE . As for NERD, it has also been reported that PPIs are better than H2RAs and placebo, although the effect of antacid medication upon NERD patients is smaller than that upon RE patients . Based on these many previous studies, almost all guidelines worldwide recommend the use of antacids, especially PPIs [11, 12, 37].
Our results clearly demonstrate that many patients with digestive drug medication (PPIs, H2RAs, and others) are suffering from GERD symptoms reflected as high FSSG scores. In other words, it is indicated that present-day digestive medicine could not fully relieve the GERD symptoms. For both the PPI users and H2RA users (Tables 3 and 4), inadequate sleep and some dietary habits show significant correlation with GERD symptoms, which suggests that improving the quality of sleep and ordered dietary habits should be recommended to them. Actually, in Japan today, stronger antacids, such as higher doses of PPIs, are eagerly expected by many gastroenterologists in clinical situations and/or daily bedside visits. Our results suggest that development of more effective digestive drugs or improvement of the usage of present-day agents is necessary.
Characteristic background factors correlated to FSSG scores among PPI users and H2RA users
It should be noted that there are some distinctive characteristics for background factors of PPI users and H2RA users (Tables 3 and 4). One is the marked difference in the correlation of gender; female gender is the strongest background factor of the 371 PPI users, whereas it shows no significant correlation among the 539 H2RA users. It may reflect that the rates of subjects with the most severe GERD symptoms (FSSG scores of 21 to 48) were high in women (1.89%) compared with men (1.31%). At present, however, the precise mechanism of the difference between PPI users and H2RA users is not elucidated.
Another characteristic is the positive correlation of the use of antihypertensive drugs for GERD symptoms in both PPI users and H2RA users (Tables 3 and 4). Though there have been very few studies showing the association of GERD with hypertension or antihypertensive drug use, a cross-sectional study from Japan reported positive correlation between hypertension and reflux esophagitis . They speculated the effect of decreasing the lower esophageal sphincter pressure by calcium antagonists, the most frequently used antihypertensive drugs in Japan [38, 39]. In our results, however, the significant correlation of antihypertensive drug use was detected in PPI users and H2RA users only, and not detected in the total 19,864 subjects. We have no speculation for this correlation at present; statistical analysis is needed in the future, together with precise data of the kind of antihypertensive drugs and measured blood pressures of the subjects.
One of limitations of our study was that the study subjects may tend to be comprised of rather wealthy people, as the fee for participating in the medical checkup program was not too expensive but also not too cheap. Therefore, our study result could not completely reflect the population-based data of Japanese or East Asian people. Another limitation of our study was the lack of information on dose and type of PPIs and H2RAs. More detailed information of orally taken antacids might more precisely show their influence on FSSG scores.
A large-scale study in Japan revealed that many lifestyle-related factors have correlation with high scores of FSSG (Frequency Scale for the Symptoms of GERD). Poor quality of sleep and irregular dietary habits are the strongest risk factors among them. The present-day usual dose of PPI or H2RA cannot fully relieve GERD symptoms.
body mass index
Frequency Scale for the Symptoms of GERD
gastroesophageal reflux disease
histamine H2 receptor antagonist
non-erosive reflux disease
non-steroidal anti-inflammatory drugs
proton pump inhibitor
Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R: The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006, 101: 1900-1920. quiz 1943
el-Serag HB, Sonnenberg A: Opposing time trends of peptic ulcer and reflux disease. Gut. 1998, 43: 327-333.
Lind T, Havelund T, Carlsson R, Anker-Hansen O, Glise H, Hernqvist H, Junghard O, Lauritsen K, Lundell L, Pedersen SA, Stubberod A: Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol. 1997, 32: 974-979.
Fass R, Fennerty MB, Vakil N: Nonerosive reflux disease--current concepts and dilemmas. Am J Gastroenterol. 2001, 96: 303-314.
El-Serag HB: Epidemiology of non-erosive reflux disease. Digestion. 2008, 78 (Suppl 1): 6-10.
Bytzer P: Goals of therapy and guidelines for treatment success in symptomatic gastroesophageal reflux disease patients. Am J Gastroenterol. 2003, 98: S31-39.
Pisegna J, Holtmann G, Howden CW, Katelaris PH, Sharma P, Spechler S, Triadafilopoulos G, Tytgat G: Review article: oesophageal complications and consequences of persistent gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2004, 20 (Suppl 9): 47-56.
Meineche-Schmidt V, Juhl HH, Ostergaard JE, Luckow A, Hvenegaard A: Costs and efficacy of three different esomeprazole treatment strategies for long-term management of gastro-oesophageal reflux symptoms in primary care. Aliment Pharmacol Ther. 2004, 19: 907-915.
Pace F, Negrini C, Wiklund I, Rossi C, Savarino V: Quality of life in acute and maintenance treatment of non-erosive and mild erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2005, 22: 349-356.
Fujiwara Y, Takahashi S, Arakawa T, Sollano JD, Zhu Q, Kachintorn U, Rani AA, Hahm KB, Joh T, Kinoshita Y, Matsumoto T, Naito Y, Takeuchi K, Furuta K, Terano A: A 2008 questionnaire-based survey of gastroesophageal reflux disease and related diseases by physicians in East Asian countries. Digestion. 2009, 80: 119-128.
DeVault KR, Castell DO: Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2005, 100: 190-200.
Katelaris P, Holloway R, Talley N, Gotley D, Williams S, Dent J: Gastro-oesophageal reflux disease in adults: Guidelines for clinicians. J Gastroenterol Hepatol. 2002, 17: 825-833.
Carlsson R, Dent J, Bolling-Sternevald E, Johnsson F, Junghard O, Lauritsen K, Riley S, Lundell L: The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand J Gastroenterol. 1998, 33: 1023-1029.
Manterola C, Munoz S, Grande L, Bustos L: Initial validation of a questionnaire for detecting gastroesophageal reflux disease in epidemiological settings. J Clin Epidemiol. 2002, 55: 1041-1045.
Kusano M, Shimoyama Y, Sugimoto S, Kawamura O, Maeda M, Minashi K, Kuribayashi S, Higuchi T, Zai H, Ino K, Horikoshi T, Sugiyama T, Toki M, Ohwada T, Mori M: Development and evaluation of FSSG: frequency scale for the symptoms of GERD. J Gastroenterol. 2004, 39: 888-891.
Zimmerman J: Validation of a brief inventory for diagnosis and monitoring of symptomatic gastro-oesophageal reflux. Scand J Gastroenterol. 2004, 39: 212-216.
Klauser AG, Schindlbeck NE, Muller-Lissner SA: Symptoms in gastro-oesophageal reflux disease. Lancet. 1990, 335: 205-208.
Danjo A, Yamaguchi K, Fujimoto K, Saitoh T, Inamori M, Ando T, Shimatani T, Adachi K, Kinjo F, Kuribayashi S, Mitsufuji S, Fujiwara Y, Koyama S, Akiyama J, Takagi A, Manabe N, Miwa H, Shimoyama Y, Kusano M: Comparison of endoscopic findings with symptom assessment systems (FSSG and QUEST) for gastroesophageal reflux disease in Japanese centres. J Gastroenterol Hepatol. 2009, 24: 633-638.
Moayyedi P, Talley NJ: Gastro-oesophageal reflux disease. Lancet. 2006, 367: 2086-2100.
Dent J, El-Serag HB, Wallander MA, Johansson S: Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2005, 54: 710-717.
Lagergren J: Influence of obesity on the risk of esophageal disorders. Nat Rev Gastroenterol Hepatol. 2011, 8: 340-347.
Zagari RM, Fuccio L, Wallander MA, Johansson S, Fiocca R, Casanova S, Farahmand BY, Winchester CC, Roda E, Bazzoli F: Gastro-oesophageal reflux symptoms, oesophagitis and Barrett's oesophagus in the general population: the Loiano-Monghidoro study. Gut. 2008, 57: 1354-1359.
Yasaka S, Murakami K, Abe T, Anan J, Mizukami K, Tanahashi J, Okimoto T, Kodama M, Kudo Y, Kawasaki H, Fujioka T: Evaluation of esophageal function in patients with gastroesophageal reflux disease using transnasal endoscopy. J Gastroenterol Hepatol. 2009, 24: 1677-1682.
Miyamoto M, Haruma K, Takeuchi K, Kuwabara M: Frequency scale for symptoms of gastroesophageal reflux disease predicts the need for addition of prokinetics to proton pump inhibitor therapy. J Gastroenterol Hepatol. 2008, 23: 746-751.
Furuta T, Shimatani T, Sugimoto M, Ishihara S, Fujiwara Y, Kusano M, Koike T, Hongo M, Chiba T, Kinoshita Y: Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research Group in Japan. J Gastroenterol. 2011, 46: 1273-1283.
Sakamoto Y, Inamori M, Iwasaki T, Lida H, Endo H, Hosono K, Ikeda T, Fujita K, Yoneda M, Takahashi H, Koide T, Tokoro C, Goto A, Abe Y, Kirikoshi H, Kobayashi N, Kubota K, Saito S, Nakajima A: Relationship between upper gastrointestinal symptoms and diet therapy: examination using frequency scale for the symptoms of gastroesophageal reflux disease. Hepatogastroenterology. 2010, 57: 1635-1638.
Hampel H, Abraham NS, El-Serag HB: Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med. 2005, 143: 199-211.
Friedenberg FK, Xanthopoulos M, Foster GD, Richter JE: The association between gastroesophageal reflux disease and obesity. Am J Gastroenterol. 2008, 103: 2111-2122.
Corley DA, Kubo A: Body mass index and gastroesophageal reflux disease: a systematic review and meta-analysis. Am J Gastroenterol. 2006, 101: 2619-2628.
Fass R: Effect of gastroesophageal reflux disease on sleep. J Gastroenterol Hepatol. 2010, 25 (Suppl 1): S41-44.
Fujiwara Y, Machida A, Watanabe Y, Shiba M, Tominaga K, Watanabe T, Oshitani N, Higuchi K, Arakawa T: Association between dinner-to-bed time and gastro-esophageal reflux disease. Am J Gastroenterol. 2005, 100: 2633-2636.
Jansson C, Nordenstedt H, Wallander MA, Johansson S, Johnsen R, Hveem K, Lagergren J: A population-based study showing an association between gastroesophageal reflux disease and sleep problems. Clin Gastroenterol Hepatol. 2009, 7: 960-965.
Mody R, Bolge SC, Kannan H, Fass R: Effects of gastroesophageal reflux disease on sleep and outcomes. Clin Gastroenterol Hepatol. 2009, 7: 953-959.
Bajaj JS, Bajaj S, Dua KS, Jaradeh S, Rittmann T, Hofmann C, Shaker R: Influence of sleep stages on esophago-upper esophageal sphincter contractile reflex and secondary esophageal peristalsis. Gastroenterology. 2006, 130: 17-25.
Schey R, Dickman R, Parthasarathy S, Quan SF, Wendel C, Merchant J, Powers J, Han B, van Handel D, Fass R: Sleep deprivation is hyperalgesic in patients with gastroesophageal reflux disease. Gastroenterology. 2007, 133: 1787-1795.
van Pinxteren B, Numans ME, Bonis PA, Lau J: Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2004, CD002095.
Japanese Society of Gastroenterology: Gastroesophageal reflux. Nihon Shokakibyo Gakkai Zasshi. 2009, 1-119. Suppl I
Moki F, Kusano M, Mizuide M, Shimoyama Y, Kawamura O, Takagi H, Imai T, Mori M: Association between reflux oesophagitis and features of the metabolic syndrome in Japan. Aliment Pharmacol Ther. 2007, 26: 1069-1075.
Hongo M, Traube M, McAllister RG, McCallum RW: Effects of nifedipine on esophageal motor function in humans: correlation with plasma nifedipine concentration. Gastroenterology. 1984, 86: 8-12.
The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1741-7015/10/45/prepub
We are grateful to Mr. Tetsuo Tadokoro and his colleagues (SANRITSU Corporation, Chiba-city, Japan) for assistance in sample transport. We also thank Mr. Minoru Okada, Mr. Masanori Fujiwara, Mr. Masami Muraoka, Mr. Koichi Yamashita, Mr. Hiroyuki Kamata, and Mr. Nao Iida (Kameda Medical Center Makuhari, Chiba-shi, Chiba, Japan) for assistance with establishment and maintenance of the study database.
This work was supported in part by a grant from Chiyoda Mutual Life Foundation, in part by a grant from the Shimabara Science Promotion Foundation, and also in part by a grant from the Clinical Research Grant from St. Luke's Life Science Institute.
The authors declare that they have no competing interests.
NY contributed to the study concept and design, acquisition of data, analysis and interpretation of data, statistical analysis, and drafting of the manuscript. SM participated in critical revision of the manuscript for important intellectual content, analysis and interpretation of data. IA critically revised the manuscript for important intellectual content. RM contributed to acquisition of data, while TS participated in support of statistical analysis. MK, CT, KN, SO, SK and CMacquired data, YT analyzed and interpreted data. MF contributed to the critical revision of the manuscript for important intellectual content and to administrative support. TM and KK participated in study concept and design and study supervision. We confirm that all authors checked and approved the final version of the manuscript.
About this article
Cite this article
Yamamichi, N., Mochizuki, S., Asada-Hirayama, I. et al. Lifestyle factors affecting gastroesophageal reflux disease symptoms: a cross-sectional study of healthy 19864 adults using FSSG scores. BMC Med 10, 45 (2012) doi:10.1186/1741-7015-10-45
- gastroesophageal reflux disease (GERD)
- FSSG (Frequency Scale for the Symptoms of GERD)
- quality of sleep
- dietary habits
- proton pump inhibitor (PPI)
- histamine H2-receptor antagonist (H2RA)